Propanc Biopharma Files 8-K: Agreements, Obligations, Equity Sales
Ticker: PPCB · Form: 8-K · Filed: Dec 20, 2024 · CIK: 1517681
| Field | Detail |
|---|---|
| Company | Propanc Biopharma, Inc. (PPCB) |
| Form Type | 8-K |
| Filed Date | Dec 20, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $22,000, $20,000, $0.001, $0.0003, $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, financial-obligation, equity-sale
TL;DR
Propanc Biopharma inked a deal, took on debt, and sold stock on Dec 16th.
AI Summary
On December 16, 2024, Propanc Biopharma, Inc. entered into a material definitive agreement. The company also incurred a direct financial obligation or an obligation under an off-balance sheet arrangement. Additionally, the filing indicates unregistered sales of equity securities and includes financial statements and exhibits.
Why It Matters
This 8-K filing signals significant corporate actions by Propanc Biopharma, including new agreements, financial obligations, and equity transactions, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing details material definitive agreements, financial obligations, and unregistered equity sales, which can introduce financial and operational risks.
Key Players & Entities
- Propanc Biopharma, Inc. (company) — Registrant
- December 16, 2024 (date) — Date of earliest event reported
FAQ
What type of material definitive agreement did Propanc Biopharma, Inc. enter into?
The filing indicates Propanc Biopharma, Inc. entered into a material definitive agreement on December 16, 2024, but the specific details of the agreement are not provided in the excerpt.
What is the nature of the direct financial obligation or off-balance sheet arrangement?
The filing states that Propanc Biopharma, Inc. has a direct financial obligation or an obligation under an off-balance sheet arrangement, but the specifics are not detailed in the provided text.
When were the unregistered sales of equity securities made?
The filing mentions unregistered sales of equity securities by Propanc Biopharma, Inc., but the exact date of these sales is not specified in the excerpt.
What is the Commission File Number for Propanc Biopharma, Inc.?
The Commission File Number for Propanc Biopharma, Inc. is 000-54878.
What is the business address of Propanc Biopharma, Inc.?
The business address of Propanc Biopharma, Inc. is 302, 6 Butler Street, Camberwell, VIC, 3124, Australia.
Filing Stats: 1,598 words · 6 min read · ~5 pages · Grade level 12.1 · Accepted 2024-12-20 17:30:05
Key Financial Figures
- $22,000 — ny in the aggregate principal amount of $22,000 (the "Note"), for a purchase price of $
- $20,000 — 0 (the "Note"), for a purchase price of $20,000. The Company intends to use the net pro
- $0.001 — common stock of the Company, par value $0.001 per share (the "Common Stock"), at the
- $0.0003 — onversion Shares") at a price per share $0.0003. per share, Provided, however, that in
- $0.0001 — then the Fixed Price shall be equal to $0.0001 per share. In the Event of Default, the
- $49,200 — ny in the aggregate principal amount of $49,200 (the "Note"), for a purchase price of $
- $41,000 — 0 (the "Note"), for a purchase price of $41,000. The Company intends to use the net pro
- $49,200.00 — on the Issuance Date to the Principal ($49,200.00 * fifteen percent (15%) = $7,380.00). A
- $7,380.00 — l ($49,200.00 * fifteen percent (15%) = $7,380.00). Accrued, unpaid interest and outstand
- $28,290 — ts, with the first on June 15, 2025 for $28,290.00, and the other four payments on July
- $56,580.00 — 2025 (a total payback to the Holder of $56,580.00). The Company shall have a five (5) day
Filing Documents
- form8-k.htm (8-K) — 49KB
- ex4-1.htm (EX-4.1) — 66KB
- ex4-2.htm (EX-4.2) — 97KB
- ex10-1.htm (EX-10.1) — 76KB
- ex10-2.htm (EX-10.2) — 76KB
- ex10-2_01.jpg (GRAPHIC) — 3KB
- image_001.jpg (GRAPHIC) — 2KB
- 0001493152-24-051125.txt ( ) — 610KB
- ppcb-20241216.xsd (EX-101.SCH) — 3KB
- ppcb-20241216_lab.xml (EX-101.LAB) — 33KB
- ppcb-20241216_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 20, 2024 PROPANC BIOPHARMA, INC. By: /s/ James Nathanielsz Name: James Nathanielsz Title: Chief Executive Officer and Chief Financial Officer